SEARCH

SEARCH BY CITATION

References

  • 1
    Staschke KA, Colacino JM. Drug discovery and development of antiviral agents for the treatment of chronic hepatitis B virus infection. Prog Drug Res 2001; Spec: 111183.
  • 2
    Seeger C, Mason WS. Hepatitis B virus biology. Microbiol Mol Biol Rev 2000; 64: 5168.
  • 3
    Zoulim F. Detection of hepatitis B virus resistance to antivirals. J Clin Virol 2001; 21: 243253.
  • 4
    Delaney WET, Edwards R, Colledge D, Shaw T, Torresi J, Miller TG, et al. Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus. Antimicrob Agents Chemother 2001; 45: 17051713.
  • 5
    Zoulim F. A preliminary benefit-risk assessment of Lamivudine for the treatment of chronic hepatitis B virus infection. Drug Saf 2002; 25: 497510.
  • 6
    Papatheodoridis GV, Dimou E, Papadimitropoulos V. Nucleoside analogues for chronic hepatitis B: antiviral efficacy and viral resistance. Am J Gastroenterol 2002; 97: 16181628.
    Direct Link:
  • 7
    Fischer KP, Gutfreund KS, Tyrrell DL. Lamivudine resistance in hepatitis B: mechanisms and clinical implications. Drug Resist Updat 2001; 4: 118128.
  • 8
    Lai CL, Dienstag J, Schiff E, Leung NW, Arkins M, Hunt C, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003; 36: 687696.
  • 9
    Villeneuve JP, Durantel D, Durantel S, Westland C, Xiong S, Brosgart CL, et al. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol 2003; 39: 10851089.
  • 10
    Angus P, Vaughan R, Xiong S, Yang H, Delaney W, Gibbs C, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003; 125: 292297.
  • 11
    Siegneres B, Pichoud C, Martin P, Furman P, Trepo C, Zoulim F. Inhibitory activity of dioxolane purine analogs on wild-type and lamivudineresistant mutants of hepadnaviruses. Hepatology 2002; 36: 710722.
  • 12
    Delaney WET, Locarnini S, Shaw T. Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation. Antivir Chem Chemother 2001; 12: 135.
  • 13
    Das K, Xiong X, Yang H, Westland CE, Gibbs CS, Sarafianos SG, et al. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC). J Virol 2001; 75: 47714779.
  • 14
    Hanna GJ, D'Aquila RT. Clinical use of genotypic and phenotypic drug resistance testing to monitor antiretroviral chemotherapy. Clin Infect Dis 2001; 32: 774782.
  • 15
    Lerma JG, Heneine W. Resistance of human immunodeficiency virus type 1 to reverse transcriptase and protease inhibitors: genotypic and phenotypic testing. J Clin Virol 2001; 21: 197212.
  • 16
    Yang H, Westland C, Xiong S, Delaney WET. In vitro antiviral susceptibility of full-length clinical hepatitis B virus isolates cloned with a novel expression vector. Antiviral Res 2004; 61: 2736.
  • 17
    Pichoud C, Seigneres B, Wang Z, Trepo C, Zoulim F. Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance. Hepatology 1999; 29: 230237.
  • 18
    Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998; 27: 16701677.
  • 19
    Bock CT, Tillmann HL, Torresi J, Klempnauer J, Locarnini S, Manns MP, et al. Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation. Gastroenterology 2002; 122: 264273.
  • 20
    Gunther S, Li BC, Miska S, Kruger DH, Meisel H, Will H. A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients. J Virol 1995; 69: 54375444.
  • 21
    Gunther S, Sommer G, Von Breunig F, Iwanska A, Kalinina T, Sterneck M, et al. Amplification of full-length hepatitis B virus genomes from samples from patients with low levels of viremia: frequency and functional consequences of PCR-introduced mutations. J Clin Micronbiol 1998; 36: 531538.
  • 22
    Sambrook J, Russell DW. Molecular Cloning: A Laboratory Manual. Vol. 3, 3rd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 2001.
  • 23
    Seeger C, Ganem D, Varmus HE. Biochemical and genetic evidence for the hepatitis B virus replication strategy. Science 1986; 232: 477484.
  • 24
    Summers J, Mason WS. Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate. Cell 1982; 29: 403415.
  • 25
    Fallows DA, Goff SP. Mutations in the epsilon sequences of human hepatitis B virus affect both RNA encapsidation and reverse transcription. J Virol 1995; 69: 30673073.
  • 26
    Seeger C, Baldwin B, Tennant BC. Expression of infectious woodchuck hepatitis virus in murine and avian fibroblasts. J Virol 1989; 63: 46654669.
  • 27
    Ladner SK, Miller TJ, Otto MJ, King RW. The hepatitis B virus M539V polymerase variation responsible for 3TC resistance also confers crossresistance to other nucleoside analogues. Antivir Chem Chemother 1998; 9: 6572.
  • 28
    Gunther S, Fischer L, Pult I, Sterneck M, Will H. Naturally occurring variants of hepatitis B virus. Adv Virus Res 1999; 52: 25137.
  • 29
    Chen RY, Edwards R, Shaw T, Colledge D, Delaney WET, Isom H, et al. Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in virro. Hepatology 2003; 37: 2735.
  • 30
    Galibert F, Mandart E, Fitoussi F, Tiollais P, Charnay P. Nucleotide sequence of the hepatitis B virus genome (subtype ayw) cloned in E. coli. Nature 1979; 281: 646650.